MicuRx Pharmaceuticals, Inc. Better Therapy Through Superior Medicines Discovery MicuRx undertakes a highly efficient "de-risked" approach to expediently build a strong pipeline of pre-clinical and clinical products by focusing its innovative research on existing classes of under-explored but validated anti-infective structures. Based on advanced analysis of medical needs and identification of new scientific approaches to design superior pharmaceuticals, MicuRx team applies its unique expertise and creativity towards an expedient delivery of best-in-class agents with a blockbuster potential. With initial focus on antifungal and antibacterial chemotypes, this revolutionary strategy seeks to deliver IND candidates in a record short time. Development MicuRx is in the process of in-licensing of several advanced clinical development candidates from the global pharmaceutical companies. These anti-infective products address specific unmet medical needs. Using its extensive network and experience, MicuRx will focus on the development of these agents for North America and Asia markets, and will collaborate with global pharmaceutical companies to cover other regional markets.